ICCC - NASDAQ

ImmuCell Corporation

ICCC·NASDAQ

$9.87

-1.8%

HealthcareBiotechnology

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$89.29M

EPS-0.1200

P/E Ratio-82.25

Earnings Date08/13/2026

42.53M

Assets

-6%

3Y-5.0%

5Y+5.0%

10Y+72.0%

15.48M

Total Liabilities

-12%

3Y+7.0%

5Y+28.0%

10Y+211.0%

27.06M

Total Equity

-2%

3Y-11.0%

5Y-4.0%

10Y+37.0%

ImmuCell Corporation Funding & Solvency Profile

ICCC · NASDAQ

Current Assets

Cash & Cash Equivalents3.81M

Net Receivables3.42M

Inventory9.27M

Other Current Assets31.38K

Total Current Assets17 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets95.56K

Long-Term Investments0.00

Other Non-Current Assets25.49M

Total Non-Current Assets25 M

Total Assets

42.53M

Financial Health Analysis

Current Ratio

4.26x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.57x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

13 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

40% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ImmuCell Corporation Balance Sheet

ICCC • NASDAQ

ImmuCell Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	3.8M	3.8M	978.7K	5.8M	10.2M	7.9M	8.8M	2.5M	3.8M	5.2M	1.6M	850K	2.3M	2.7M	781.5K	1.4M	975.5K	1.2M	1.2M	1.3M
Short-Term Investments	0.0	0.0	0.0	0.0	-468.0	0.0	2.5M	0.0	0.0	5.5M	4.5M	2.5M	3M	2.2M	4.2M	3.2M	3.6M	3.9M	4.2M	5.3M
Cash & Short-Term Investments	3.8M	3.8M	978.7K	5.8M	10.2M	7.9M	8.8M	2.5M	3.8M	10.6M	6M	3.3M	5.3M	4.9M	5M	4.6M	4.6M	5.1M	5.4M	6.6M
Net Receivables	3.4M	3.8M	2.2M	1.8M	2.7M	1.9M	1.7M	1.4M	1.5M	1.1M	745.1K	1M	631.4K	611.4K	383.8K	497.5K	415.5K	894.6K	920K	620.7K
Accounts Receivables	3.4M	3.8M	2.2M	1.8M	2.7M	1.8M	1.6M	932.3K	1.3M	992.4K	718.1K	988.8K	595.7K	611.4K	346.4K	465.3K	390.2K	480.8K	712.2K	524K
Other Receivables	0.0	40.6K	0.0	42.2K	26.5K	67.6K	40.5K	493.3K	149.6K	144.8K	27K	16.5K	35.7K	0.0	36.7K	31.3K	24K	51.4K	207.7K	96.8K
Inventory	9.3M	7.1M	7.8M	6M	3.1M	2.1M	2.5M	2.3M	2M	2.1M	870.2K	945.8K	1.2M	1.6M	1.7M	1.6M	1.1M	596.4K	588.6K	789.2K
Prepaids	420.5K	360.2K	454.2K	363.9K	268.7K	252.8K	218.2K	142.5K	165.1K	126.5K	183.2K	148.4K	159.1K	157.9K	81.8K	241.2K	179.8K	92.6K	70.2K	59.7K
Other Current Assets	31.4K	0.0	39.7K	0.0	0.0	800.0	800.0	0.0	0.0	333.1K	37.3K	30.5K	15.2K	31.2K	59K	0.0	38.5K	91.5K	75.1K	267.1K
Total Current Assets	16.9M	15M	11.5M	14M	16.3M	12.2M	13.2M	6.4M	7.5M	14.3M	7.9M	5.5M	7.3M	7.4M	7.2M	7M	6.3M	6.7M	7.1M	8.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	29.9M	32.1M	30.6M	28M	28M	25.3M	26M	26.1M	9.8M	5.7M	3.8M	2.5M	2.4M	2.5M	2.7M	3M	2.9M	2.9M	1.9M
Goodwill	95.6K	95.6K	95.6K	95.6K	95.6K	95.6K	95.6K	95.6K	95.6K	95.6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	19.1K	38.2K	57.3K	76.4K	95.5K	114.6K	133.7K	152.8K	171.9K	0.0	0.0	0.0	0.0	0.0	0.0	900.0	31.9K	66.7K	546.4K
Goodwill & Intangible Assets	95.6K	114.7K	133.8K	152.9K	172K	191.1K	210.2K	229.3K	248.4K	267.5K	0.0	0.0	0.0	0.0	0.0	0.0	900.0	31.9K	66.7K	546.4K
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.2K	0.0	0.0	487K	496K	0.0	0.0	0.0	0.0	0.0	0.0	-265M	-316.2M
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-40.2K	472.7K	201K	471.7K	1.2M	1.2M	1.2M	1.3M	1M	698.1K	431.7K	340K	583.2K
Other Non-Current Assets	25.5M	33.4K	57.7K	76.6K	26.1K	26.2K	26.9K	53.2K	920.0	34.3K	49.7K	18.9K	13.6K	63.6K	19K	34K	0.0	0.0	265M	316.2M
Total Non-Current Assets	25.6M	30.1M	32.3M	30.9M	28.2M	28.2M	25.5M	26.3M	26.8M	10.3M	6.7M	5.6M	3.7M	3.7M	3.8M	3.8M	3.7M	3.4M	3.3M	3M
Other Assets	0.0	0.0	0.0	351.0	312.0	406.0	164.0	168.0	44.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	42.5M	45.1M	43.8M	44.9M	44.5M	40.4M	38.7M	32.7M	34.3M	24.7M	14.6M	11.1M	11M	11M	11M	10.8M	10M	10.1M	10.4M	11.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	803K	949.5K	890.8K	794.9K	747.2K	602.3K	572.2K	603.7K	1.2M	1.5M	199.1K	456.2K	199.7K	228.7K	149.9K	110.6K	139.9K	101.6K	118.3K	489.9K
Accounts Payable	796.3K	943.6K	887.7K	790K	745K	602.3K	402K	603.7K	580.5K	1.5M	199.1K	456.2K	152.2K	228.7K	149.9K	105.7K	139.9K	101.6K	118.3K	249.5K
Other Payables	6.7K	5.8K	3.1K	4.9K	2.1K	0.0	340.4K	0.0	1.3M	0.0	0.0	0.0	95.1K	0.0	0.0	4.8K	0.0	0.0	0.0	240.3K
Accrued Expenses	1.5M	1.5M	943K	1.2M	867.1K	747.9K	648.4K	616.9K	501.4K	384.5K	461.6K	395.5K	222K	255.6K	303.9K	136K	222.9K	382.9K	237.2K	107.7K
Short Term Debt	1.6M	1.5M	1.4M	1M	812.2K	760.3K	1.3M	1.3M	316.6K	133.3K	130.8K	150.4K	190.4K	181.5K	173K	42.4K	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	85.5K	432.1K	644.3K	31.8K	108K	100.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	3.1K	4.9K	2.1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-429K	0.0	0.0	240.3M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.1K	33.9K	0.0	6.7K	0.0	0.0	8.3K	0.0	0.0	3K	0.0	632.6K
Other Current Liabilities	0.0	0.0	306.8K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5K	0.0	23.5K	0.0	0.0	236.1K	0.0	0.0	0.0	819.3K
Total Current Liabilities	4M	4.4M	4.2M	3.1M	2.5M	2.2M	2.5M	2.6M	2.1M	2.1M	817.6K	1M	635.6K	665.8K	635K	525K	362.8K	484.5K	355.5K	1.4M
NON-CURRENT LIABILITIES
Long Term Debt	7.5M	9M	10.5M	9.2M	8.3M	8.7M	7.1M	8.4M	8.6M	2.9M	3.1M	745.9K	896.2K	1.1M	1.3M	943.8K	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-19.6M	-1.2B	-1.2B	-1.2B	0.0	0.0	0.0	0.0	0.0	615M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.6M	1.2B	1.2B	1.2B	0.0	4.8M	0.0	0.0	340M	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	58.5K	0.0	996.0	37.3K	78.5K	38.8K	33K	83.4K	67.9K	0.0	0.0	0.0	-340M	0.0
Total Non-Current Liabilities	11.5M	13.2M	14.6M	11.4M	9.4M	9.9M	7.2M	8.4M	8.6M	2.9M	3.2M	784.7K	929.2K	1.2M	1.3M	943.8K	0.0	0.0	340M	615K
Other Liabilities	0.0	0.0	0.0	400.0	252.0	606.0	442.0	502.0	-16.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-340M	0.0
Capital Lease Obligations	4.1M	4.6M	4.7M	2.2M	1.1M	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	15.5M	17.6M	18.8M	14.5M	11.9M	12.1M	9.7M	11M	10.7M	5M	4M	1.8M	1.6M	1.8M	2M	1.5M	362.8K	484.5K	355.5K	2M
SHAREHOLDERS' EQUITY
Treasury Stock	-130.8K	-138.5K	-138.5K	-147.2K	-158.2K	-175.4K	-188.3K	-204.9K	-407.9K	-431.9K	-450.9K	-512.2K	-514.3K	-529.7K	-562.5K	-628.9K	-635.5K	-801.8K	-802.9K	-762.6K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	60.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	910.6K	904.2K	781.4K	781.4K	781.4K	729.9K	729.9K	566.3K	566.3K	504.5K	326.1K	326.1K	326.1K	326.1K	326.1K	326.1K	326.1K	326.1K	326.1K	326.1K
Additional Paid-In Capital	41.5M	40.9M	36.4M	36M	35.7M	31.4M	31.1M	22.7M	22.5M	18.5M	10.2M	10M	10M	10M	9.9M	9.8M	9.8M	9.7M	9.7M	9.6M
Retained Earnings	-15.2M	-14.2M	-12M	-6.2M	-3.7M	-3.7M	-2.6M	-1.3M	979K	1.1M	638.7K	-574.6K	-407.4K	-524.8K	-614.3K	-204.8K	179.9K	396.4K	864.9K	202.8K
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	-43.9K	30.2K	-638.0	-23.9K	-50.3K	-23.3K	-19.8K	-50.1K	-40.8K	9.6K	-2.6M	-2.3M	-1.9M	-2M
Total Stockholders' Equity	27.1M	27.5M	25M	30.4M	32.6M	28.3M	29M	21.7M	23.6M	19.7M	10.6M	9.3M	9.4M	9.2M	9M	9.3M	9.6M	9.6M	10.1M	9.3M
Total Equity	27.1M	27.5M	25M	30.4M	32.6M	28.3M	29M	21.7M	23.6M	19.7M	10.6M	9.3M	9.4M	9.2M	9M	9.3M	9.6M	9.6M	10.1M	9.3M
SUMMARY
Total Liabilities & Equity	42.5M	45.1M	43.8M	44.9M	44.5M	40.4M	38.7M	32.7M	34.3M	24.7M	14.6M	11.1M	11M	11M	11M	10.8M	10M	10.1M	10.4M	11.4M
Total Investments	0.0	0.0	0.0	0.0	-468.0	0.0	2.5M	40.2K	0.0	5.5M	5M	3M	3M	2.2M	4.2M	3.2M	3.6M	3.9M	4.2M	5.3M
Total Debt	13.2M	15.1M	16.7M	12.5M	10.3M	10.7M	8.4M	9.8M	9M	3M	3.2M	896.3K	1.1M	1.3M	1.4M	986.1K	0.0	0.0	0.0	0.0
Net Debt	9.4M	11.3M	15.7M	6.7M	89K	2.8M	-352.5K	7.2M	5.2M	-2.1M	1.7M	46.3K	-1.2M	-1.4M	659.4K	-412.8K	-975.5K	-1.2M	-1.2M	-1.3M
Shares Outstanding	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851	9,045,851

SEC Filings

ICCC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	May 13, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	May 08, 2026	May 08, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 14, 2026	April 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 08, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 18, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing

Showing 1 to 10 of 418 filings

Related Guides

Blog Categories

Continue your ICCC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.